Thrombalexin: Use of a Cytotopic Anticoagulant to Reduce Thrombotic Microangiopathy in a Highly Sensitized Model of Kidney Transplantation

Autor: Stephen Sacks, Miriam Manook, Anthony Dorling, Verna Curfman, Richard A. G. Smith, He Xu, Evelyn Branum, Andrea L. MacDonald, Kyle Freischlag, Kannan P. Samy, Stuart J. Knechtle, Janghoon Yoon, Michael S. Mulvihill, Alton B. Farris, David N. Howell, Jean Kwun, Christian Burghuber, Nizam Mamode

Publikováno v: Manook, M, Kwun, J, Burghuber, C, Samy, K, Mulvihill, M, Yoon, J, Xu, H, MacDonald, A L, Freischlag, K, Curfman, V, Branum, E, Howell, D, Farris, A B, Smith, R A, Sacks, S, Dorling, A, Mamode, N & Knechtle, S J 2017, ' Thrombalexin: use of a cytotopic anticoagulant to reduce thrombotic microangiopathy in a highly sensitized model of kidney transplantation ', American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, vol. 17, no. 8, pp. 2055-2064 . https://doi.org/10.1111/ajt.14234

Early activation of coagulation is an important factor in the initiation of innate immunity, as characterized by thrombotic microangiopathy (TMA). In transplantation, systemic anti-coagulation is difficult due to bleeding. A novel 'cytotopic' agent,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c7f498418133ff3928c31eff99180fd1
https://pubmed.ncbi.nlm.nih.gov/29083552